Premium
Preclinical study of a glycoengineered anti‐human CD20 antibody in murine models of primary cerebral and intraocular B‐cell lymphomas
Author(s) -
BAGGA RYM
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.3367.x
Subject(s) - cd20 , medicine , rituximab , lymphoma , antibody , monoclonal antibody , in vivo , cancer research , pathology , cd8 , b cell , intraocular lymphoma , immunology , immune system , biology , microbiology and biotechnology
Purpose Primary cerebral lymphomas (PCL) and primary intraocular lymphomas (PIOL), related to the systemic diffuse large B‐cell lymphoma family, are highly aggressive tumors, with poor prognosis and any specific therapy. Despite good results obtained with chemotherapy, many patients relapse and new therapeutic strategies are needed. PCL and PIOL are characterized by the presence of CD20+ lymphomatous B‐cells and as such are eligible for therapy with anti human CD20 antibodies. Methods In this study, we evaluated the efficiency of LFB‐R603, a promising glycoengineered anti‐hCD20 monoclonal antibody that displays a high affinity for FcgRIIIa (CD16) receptors, when injected intumoraly. We used a murine lymphomatous B cell line transfected with the human CD20 gene to generate two syngeneic murine models of PCL and PIOL Results After a single therapeutic injection of LFB‐R603 mAb, a strong anti‐tumor response was noted against the PCL and a less pronounced response in the PIOL model. This was linked to an inhibition of tumor growth and infiltration with CD8+ T‐cells in both models. Interestingly, therapeutic effects were much better than those obtained with the Rituximab used as a reference. Conclusion These in vivo results confirm the potential of the LFB‐R603 mAb as an innovative therapeutic approach for the treatment of PCNSL tumors.